About Imanova
Imanova is a Healthcare company based in London (United Kingdom) founded in 2011, and was acquired by Invicro in September 2017. PET and MRI imaging services for drug development are provided. Imanova offers products and services including Imaging Core Lab, Clinical Adjudication, Preclinical Imaging, eClinical, and Radiochemistry. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is IMANOVA LIMITED.
Company details
Imanova, acquired by US-based Invicro in September 2017, enables the study of the absorption, distribution, metabolism and excretion of drugs through their expertise in radiolabeling of drug candidates and Positron Emission Tomography (PET) imaging. They also offer services for visualising the candidate target engagement in vivo through PET imaging. The company also offers MRI services. Founded as a joint venture between UKs Medical Research Council and three London universities - the Imperial College London, Kings College London and University College London, the company offers preclinical and clinical imaging and novel imaging biomarker development services. Imanova claims to have developed and implemented 21 imaging biomarkers according to GMP standards since its inception. The company offer imaging biomarker development services mainly for therapeutic areas such as neurosciences, oncology, inflammation, cardiology and respiratory diseases.
- Headquarters London, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Website imanova.co.uk
- Social LinkedIn X
- Acquired by Invicro (Sep 2017)
- Legal Name Imanova Limited
- Date of Incorporation 03 Feb, 2011
- Jurisdiction LONDON, UNITED KINGDOM
Products & Services of Imanova
Imanova offers a comprehensive portfolio of products and services, including Imaging Core Lab, Clinical Adjudication, Preclinical Imaging, eClinical, and Radiochemistry.
Delivers high-quality imaging data for clinical trials worldwide.
Conducts independent reviews of trial event assessments by experts.
Supports imaging study designs for pharmaceutical R&D needs.
Offers RTSM solutions for efficient clinical trial operations.
Provides radiolabeling for agents in drug development processes.
Funding Insights of Imanova
- Total Rounds 1
- Last Round Grant — $305,722
- First Round $305,722
(Jun 2016)
- Investors Count 1
All 1 funding rounds of Imanova with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $305,722 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Imanova
Imanova has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Invicro and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Provide contract research imaging services and software | 2008 | invicro.com | Boston, United States |
Investor details for Imanova
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Imanova
3 dated milestones of Imanova across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Imanova is founded.
- Funding First funding round of $306K.
- Exit Acquired by Invicro.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Imanova (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Imanova
Imanova was founded in 2011 and raised its 1st funding round 5 years after it was founded.
Imanova is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Imanova, acquired by US-based Invicro in September 2017, enables the study of the absorption, distribution, metabolism and excretion of drugs through their expertise in radiolabeling of drug candidates and Positron Emission Tomography (PET) imaging. They also offer services for visualising the candidate target engagement in vivo through PET imaging. The company also offers MRI services. Founded as a joint venture between UKs Medical Research Council and three London universities - the Imperial College London, Kings College London and University College London, the company offers preclinical and clinical imaging and novel imaging biomarker development services. Imanova claims to have developed and implemented 21 imaging biomarkers according to GMP standards since its inception. The company offer imaging biomarker development services mainly for therapeutic areas such as neurosciences, oncology, inflammation, cardiology and respiratory diseases.
Imanova offers Imaging Core Lab, Clinical Adjudication, Preclinical Imaging, eClinical, and Radiochemistry.
Imanova has 2 investors. Key investors include Invicro, and European Union.
Imanova operates through Imanova Limited.
Yes. Imanova was acquired by Invicro in September 2017.